Last $4.76 USD
Change Today -0.33 / -6.48%
Volume 84.1K
GALT On Other Exchanges
Symbol
Exchange
NASDAQ CM
Frankfurt
NASDAQ CM
As of 8:10 PM 10/22/14 All times are local (Market data is delayed by at least 15 minutes).

galectin therapeutics inc (GALT) Key Developments

Galectin Therapeutics Inc. Elects Gilbert S. Omenn to its Board of Directors

On September 23, 2014, the Board of Directors of Galectin Therapeutics Inc. elected Gilbert S. Omenn, M.D., Ph.D. to its Board of Directors. Dr. Omenn served on the board of directors of Amgen Inc. for 27 years and of Rohm & Haas Company for 22 years. He currently serves on the boards of Esperion Therapeutics Inc., Etubics Corp., and OncoFusion Therapeutics Inc.

Pomerantz LLP Announces the Filing of Class Action Against Galectin Therapeutics, Inc. and Certain Officers

Pomerantz LLP has filed a class action lawsuit against Galectin Therapeutics, Inc. and certain of its officers. The class action, filed in United States District Court, District of Nevada, and docketed under 14-cv-01287, is on behalf of a class consisting of all persons or entities who purchased Galectin securities between January 6, 2014 and July 28, 2014, inclusive. This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws under the Securities Exchange Act of 1934 (the Exchange Act). The complaint alleges that throughout the class period, defendants made false and/or misleading statements, and failed to disclose material adverse facts about the company's business, operations, prospects and performance. Specifically, during the class period, defendants made false and/or misleading statements and/or failed to disclose that: (1) the company was utilizing the services of paid stock promoters to disseminate positive but misleading reports about Galectin's prospects; (2) moreover, GR-MD-02 did not provide the benefits suggested by Defendants when discussing the patent the company was awarded or the Phase 1 clinical trial it was conducting; and (3) as a result of the above, the company's financial statements were materially false and misleading at all relevant times.

Galectin Therapeutics, Inc. Presents at Aegis Capital 2014 Healthcare & Technology Conference, Sep-12-2014 01:00 PM

Galectin Therapeutics, Inc. Presents at Aegis Capital 2014 Healthcare & Technology Conference, Sep-12-2014 01:00 PM. Venue: The Encore at Wynn Las Vegas, 3121 Las Vegas Blvd. South, Las Vegas, NV 89109, United States. Speakers: Peter G. Traber, Chief Executive Officer, President, Chief Medical Officer and Director.

Galectin Therapeutics, Inc. Reports Consolidated Earnings Results for the Second Quarter and Six Months Ended June 30, 2014

Galectin Therapeutics, Inc. reported consolidated earnings results for the second quarter and six months ended June 30, 2014. For the quarter, the company reported total operating loss was $3.375 million compared with $2.547 million for the same period last year. Net loss applicable to common stock was $3.731 million or $0.17 basic and diluted per share compared with $11.641 million or $0.72 basic and diluted per share for the same period last year. Excluding non-cash charge, the increase in net loss applicable to common stock in the quarter ended June 30, 2014 over 2013 is primarily due to increases in clinical trial costs related to Phase 1 clinical trial, non-cash stock-based compensation expense and legal costs. For the six months, the company reported total operating loss was $8.219 million compared with $5.755 million for the same period last year. Net loss applicable to common stock was $9.139 million or $0.42 basic and diluted per share compared with $15.113 million or $0.94 basic and diluted per share for the same period last year.

The Rosen Law Firm Files Securities Class Action Against Galectin Therapeutics, Inc

The Rosen Law Firm, P.A. announces that a class action lawsuit has been filed on behalf of purchasers of Galectin Therapeutics, Inc. securities between January 6, 2014 and July 28, 2014, inclusive asserting violations of federal securities laws. According the lawsuit, Galectin and certain of its officers and directors made false and misleading statements concerning one of its lead product candidates -- GR-MD-02 that seeks to treat the liver disease NASH.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
GALT:US $4.76 USD -0.33

GALT Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for GALT.
View Industry Companies
 

Industry Analysis

GALT

Industry Average

Valuation GALT Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book 4.5x
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact GALECTIN THERAPEUTICS INC, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.